Kelyniam Global Inc. reported year-to-date revenue of $2.2 million for Q3 2025, a decrease of 12.3% compared to $2.5 million in Q3 2024. Gross profit was $1.7 million, down 13.3% from $2.0 million in the prior year period. The company reported an operating loss of $162,400, compared to operating income of $273,200 in Q3 2024. Key business developments included FDA 510(k) clearance for the Vestakeep resorbable bi-calcium phosphate implant and ongoing Value Analytics review at six major U.S. hospitals, potentially adding over $500,000 in annual recurring revenue. Kelyniam also uplisted to OTCID status on the OTC Markets Group platform.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kelyniam Global Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY20395) on November 10, 2025, and is solely responsible for the information contained therein.